Key Points
- Rahul Khara sold 6,500 shares of Disc Medicine on January 2 at an average price of $78.69 for about $511,485, trimming his stake by 14.68% to 37,793 shares (filing available with the SEC).
- Disc Medicine trades near $78.63 with a market capitalization of roughly $2.97 billion, a 52‑week range of $30.82–$99.50, and recently reported a quarterly EPS loss of ($1.77) that missed estimates.
- Analysts are mostly positive — the stock has an average rating of "Moderate Buy" and a consensus price target of $119, with several firms issuing higher targets (e.g., Cantor Fitzgerald at $153).
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $78.69, for a total value of $511,485.00. Following the sale, the insider directly owned 37,793 shares in the company, valued at $2,973,931.17. This trade represents a 14.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Disc Medicine Stock Performance
Shares of IRON opened at $78.63 on Tuesday. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -14.70 and a beta of 0.87. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average price of $87.26 and a 200 day moving average price of $71.22.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.29). Research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on IRON shares. Cantor Fitzgerald raised their price objective on Disc Medicine from $132.00 to $153.00 and gave the stock an "overweight" rating in a report on Friday, October 17th. Stifel Nicolaus assumed coverage on Disc Medicine in a research note on Monday, November 3rd. They set a "buy" rating and a $125.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Morgan Stanley increased their price objective on Disc Medicine from $90.00 to $115.00 and gave the company an "overweight" rating in a report on Thursday, October 30th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $117.00 target price on shares of Disc Medicine in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $119.00.
View Our Latest Stock Analysis on IRON
Hedge Funds Weigh In On Disc Medicine
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MetLife Investment Management LLC increased its stake in Disc Medicine by 10.9% in the 1st quarter. MetLife Investment Management LLC now owns 13,454 shares of the company's stock valued at $668,000 after buying an additional 1,322 shares during the period. Corebridge Financial Inc. lifted its stake in shares of Disc Medicine by 14.0% in the 1st quarter. Corebridge Financial Inc. now owns 11,180 shares of the company's stock worth $555,000 after acquiring an additional 1,371 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock valued at $756,000 after acquiring an additional 2,807 shares in the last quarter. Millennium Management LLC increased its stake in shares of Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company's stock worth $5,386,000 after acquiring an additional 100,620 shares during the period. Finally, Zimmer Partners LP raised its holdings in Disc Medicine by 29.6% during the first quarter. Zimmer Partners LP now owns 42,900 shares of the company's stock worth $2,130,000 after purchasing an additional 9,800 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
